NovoBliss Research Private Limited
Ahmedabad, Gujarat, India
NCT Number: NCT07162623
This is a randomized, double-blinded, single-centre, two-arms, placebo-controlled, prospective study to evaluate clinical safety, efficacy and in-use tolerability of Test Product i.e. Oziva Bioactive Gluta Fizzy Effervescent tablets in subjects with facial hyperpigmentation and dark spots.
This study is active but is not currently recruiting participants.
Notify Me21 year–55 year
All sexes
Interventional
Not applicable
Ahmedabad, Gujarat, India
A total of 60 Indian Subjects (30 Subjects per Test Product), including males and non-pregnant, non-lactating females aged between 21 and 55 years (inclusive). Indian Subjects with a Fitzpatrick skin type of III to VI must present with facial hyperpigmentation and dark spots such as tan, pimple marks, sunspots, age spots, uneven skin tone on both side of face at baseline. Participants will be randomized in a 1:1 ratio to received either test Product A or test Product B. the study aims to complete evaluation for 50 Indian Subjects (25 Subjects per Test Product).
The potential subjects will be screened as per the inclusion and exclusion criteria only after obtaining written informed consent from the subjects. Subjects will be contacted telephonically by recruiting department prior to the screening.
There will be total of 3 visits during the study. The duration of the study will be 90 Days (12 weeks) from the enrolment. Subjects will be instructed to visit the facility as per below visits:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Mode of Usage: Dissolve one effervescent tablet in a full glass of water in 200 mL. Allow it to fully dissolve before consuming. For best results, consume the solution immediately after preparation before the fizz ends.
Frequency: Once Daily Route of administration: Oral Storage Condition: Store at room temperature 15°C to 30°C, away from sunlight
Mode of Usage: Dissolve one effervescent tablet in a full glass of water in 200 mL. Allow it to fully dissolve before consuming. For best results, consume the solution immediately after preparation before the fizz ends.
Frequency: Once Daily Route of administration: Oral Storage Condition: Store at room temperature 15°C to 30°C, away from sunlight
Time frame: Baseline (Day 1) to Day 45 (±2 days) and Day 90 (±2 days)
Comparison of changes within each test product group and between product groups
Time frame: Baseline (Day 1) to Day 45 (±2 days) and Day 90 (±2 days)
Comparison of changes within each test product group and between product groups
Time frame: Baseline (Day 1) to Day 45 (±2 days) and Day 90 (±2 days)
Comparison of changes within each test product group and between product groups
Time frame: Baseline (Day 1) to Day 45 (±2 days) and Day 90 (±2 days)
Comparison of changes within each test product group and between product groups
Time frame: Baseline (Day 1) to Day 90 (±2 days)
Comparison of changes within each test product group and between product groups
Time frame: Baseline (Day 1) to Day 90 (±2 days)
Comparison of changes within each test product group and between product groups
Time frame: Baseline (Day 1) to Day 45 (±2 days) and Day 90 (±2 days)
Comparison of changes within each test product group and between product groups.
Time frame: Baseline (Day 1) to Day 45 (±2 days) and Day 90 (±2 days)
Comparison of changes within each test product group and between product groups
Time frame: Baseline (Day 1) to Day 45 (±2 days) and Day 90 (±2 days)
Comparison of changes within each test product group and between product groups
Time frame: Baseline (Day 1) to Day 45 (±2 days) and Day 90 (±2 days)
Comparison of changes within each test product group and between product groups
Time frame: Baseline (Day 1) to Day 45 (±2 days) and Day 90 (±2 days)
Comparison of changes within each test product group and between product groups
Time frame: Baseline (Day 1) to Day 45 (±2 days) and Day 90 (±2 days)
Comparison of responses within each test product group and between product groups
NovoBliss Research Pvt Ltd
Other
A Randomized, Double-Blind, Placebo-Controlled, Two-Arms, Prospective, Single-Center Clinical Study to Assess the Safety, Efficacy and In-Use Tolerability of Test Product i.e. Oziva Bioactive Gluta Fizzy in Subjects With Facial Hyperpigmentation
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07067515
Gingival Hyperpigmentaion, Hyperpigmentation
Ismailia, Egypt
View Trial DetailsNCT07725900
Dry Skin, Erythema
Semarang, Central Java, Indonesia
View Trial DetailsNCT07722351
Hyperpigmentation, Melanosis
Sosnowiec, Poland
View Trial DetailsNCT07644871
Dark Spots, Hyperpigmentation
Irving, Texas, United States
View Trial Details